$STE (Steris Plc)

$STE {{ '2016-08-09T18:00:29+0000' | timeago}} • Webcast

$STE said legacy Synergy revenue in constant currency grew low single digits during 1Q17, which is in line with expectations. Gross margin as a percentage of revenue decreased 370 BPs to 38.2%. As expected, Synergy negatively impacted year-over-year gross margin by approx. 500 BPs.

$AMGN {{ '2017-07-25T22:44:31+0000' | timeago}} • Announcement

$AMGN increased its 2017 earnings guidance to between $10.79 per share and $11.37 per share on GAAP basis, and between $12.15 per share and $12.65 per share on adjusted basis. Sales guidance was revised to a range of $22.5-23Bil.

$AMGN {{ '2017-07-25T22:43:15+0000' | timeago}} • Announcement

$AMGN reported a 15% YoY earnings growth in 2Q17 to $2.2Bil, or $2.91 per share, driven by a 4.9 percentage points increase in operating margin. Adjusted for one-time items, the company reported per-share earnings of $3.27. Revenue rose 2% to $5.8Bil.

$AMGN {{ '2017-07-25T20:50:47+0000' | timeago}} • Infographic

$AMGN Amgen Earnings AlphaGraphic: Q2 2017 highlights

$MMM {{ '2017-07-25T17:59:58+0000' | timeago}} • Webcast

$MMM said it had reduced prices of a number of products in 2Q17 to accelerate growth in areas where price seemed to be a barrier. The St Paul, Minnesota-based company added that it is currently at the peak of price declines and expects an upstick in pricing in 2H17.

$MMM {{ '2017-07-25T17:38:50+0000' | timeago}} • Webcast

$MMM, which makes Post-It notes, said it saw organic growth in three of its four Consumer segment businesses in 2Q17, namely Home Improvement, Home Supplies and Consumer Healthcare. Meanwhile, its Stationery and Office Supplies business was again impacted by inventory reductions in the US office retail and wholesale channels.

$MMM {{ '2017-07-25T17:23:43+0000' | timeago}} • Webcast

$MMM said it expects 20-25 cents per share impact from incremental strategic investments in 2H17, which is expected to drive greater productivity from its manufacturing and supply chain base.

$IVC {{ '2017-07-25T16:39:52+0000' | timeago}} • Announcement

$IVC received notice from the FDA that the company has successfully satisfied the agency's requirements under the consent decree to resume full operations at its Corporate and Taylor Street manufacturing facility in Elyria, Ohio.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$LLY {{ '2017-07-25T14:13:17+0000' | timeago}} • Announcement

$LLY, which joined hands with $NKTR recently to co-develop the autoimmune drug NKTR-358, cut down its GAAP earnings outlook for FY17 by $0.09 per share to $2.51-2.61. However, Eli Lilly lifted its non-GAAP EPS estimate to $4.10-4.20 from the prior outlook of $4.05-4.15 Revenue outlook also lifted to $22.0-22.5Bil from prior range of $21.8-22.3Bil.

$MMM {{ '2017-07-25T13:22:56+0000' | timeago}} • Infographic

$MMM 3M Earnings AlphaGraphic: Q2 2017 Highlights

$LLY {{ '2017-07-25T13:14:16+0000' | timeago}} • Announcement

Drugmaker $LLY reported a jump in its profit for the second quarter 2017, boosted by new pharma products sales and higher realized prices. Profit climbed 35% to $1.01Bil and GAAP EPS surged 34% to $0.91 versus a year ago. Revenue grew 8% to $5.82Bil and non-GAAP EPS spiked up 29% to $1.11.

$MMM {{ '2017-07-25T12:44:59+0000' | timeago}} • Announcement

On a geographic basis, $MMM saw highest growth in Asia Pacific region in 2Q17, where sales grew 8.3%. In other locations, sales increased 2.5% in Latin America/Canada, and 0.5% in the US. Meanwhile, total sales declined 3.6% in EMEA.

$MMM {{ '2017-07-25T12:41:50+0000' | timeago}} • Announcement

In 2Q17, $MMM's sales grew 7.5% in Electronics and Energy, 2.5% in Industrial and 1.8% in Health Care. Consumer continued to be an area of concern, where the company managed just 0.5% growth. Meanwhile, sales declined 0.9% in Safety and Graphics segment.

$LLY {{ '2017-07-25T12:32:52+0000' | timeago}} • Infographic

$LLY Eli Lilly and Company Earnings AlphaGraphic: Q2 2017 Highlights

$MMM {{ '2017-07-25T12:23:15+0000' | timeago}} • Announcement

$MMM raised the lower end of its FY17 EPS outlook. It now expects GAAP EPS of $8.80-9.05, compared to the earlier forecast of $8.70-9.05.

$MMM {{ '2017-07-25T12:16:01+0000' | timeago}} • Announcement

Manufacturing company $MMM reported 24% jump in EPS to $2.58 in 2Q17, as sales inched up 2% to $7.8Bil. The sales growth was driven by its Electronics and Energy segment, as well as the Asia Pacific operations. Net income attributable to 3M was $1.58Bil, compared to $1.29Bil a year ago. Operating margin grew 3.6 percentage points to 28%.

$LLY {{ '2017-07-24T19:31:07+0000' | timeago}} • Announcement

As a result of the deal signed with Nektar on co-developing autoimmune drug NKTR-358, $LLY expects a charge of about $0.09 per share to its 2017 earnings. Eli Lilly cut down its 2017 GAAP EPS outlook by $0.09 to $2.51-2.61 from its previous outlook of $2.60-2.70 and it didn't change the estimate for non-GAAP EPS because of the Nektar partnership.

$LLY {{ '2017-07-24T18:19:30+0000' | timeago}} • Announcement

$LLY to co-develop $NKTR's autoimmune drug NKTR-358. Under the deal terms, Eli Lilly will pay Nektar Therapeutics an upfront payment of $150MM and up to $250MM if development and regulatory milestones are achieved. Nektar to complete Phase 1 clinical development and will bear 25% of Phase 2 cost. $LLY will bear 75% of the Phase 2 development cost.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
PII (Polaris Industries Inc.)
Thursday, July 20 2017 - 2:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
NTIC (Northern Technologies International Corp.)
Thursday, July 13 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
IVC (Invacare Corporation)
Tuesday, May 9 2017 - 12:30pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
SRCL (Stericycle, Inc.)
Thursday, May 4 2017 - 9:00pm
KAMN (Kaman Corporation)
Thursday, May 4 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
CLX (The Clorox Company)
Wednesday, May 3 2017 - 5:30pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
HCA (HCA Holdings, Inc.)
Tuesday, May 2 2017 - 3:00pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
TRS (TriMas Corporation)
Thursday, April 27 2017 - 2:00pm

AlphaGraphics you may like